Glutamate, the brain’s main excitatory chemical, locks onto AMPA receptors to enable thought, sensation, and memory—but when these receptors malfunction, they contribute to stroke damage, epilepsy, motor neuron disease, and brain tumours. This project tackles a fundamental gap: how do ‘auxiliary’ proteins—TARPs and cornichons—control the behaviour of AMPA receptors? Without knowing which auxiliary proteins govern which receptor subtypes, drug designers cannot selectively target the harmful ones while leaving healthy signalling intact. The researchers will use electrophysiology, imaging, and molecular tools to map how these proteins influence drug responses, identify the regulators of calcium-permeable AMPARs (the subtype linked to disease), and explore their role in inflammatory pain and white matter damage. This is fundamental science with no immediate clinical product. But understanding the molecular levers that tune AMPA receptors could eventually guide drug discovery for conditions where cognition declines—Alzheimer’s and Parkinson’s—or where receptor overactivity causes brain injury. Past work on receptor auxiliary subunits has already reshaped how neuroscientists think about synaptic signalling; this project aims to complete that picture.
View original technical description
The functions of our brain rely on the chemical communication that takes place between its myriad cells. One of the most important of these chemicals is glutamate, a neurotransmitter responsible for a majority of fast excitatory signaling. Glutamate acts by binding to receptor proteins at points of contact between nerve cells, and most key features of this excitatory signaling are shaped by the basic properties of one specific class of glutamate receptor - the AMPA receptors (AMPARs). AMPARs are ubiquitous; their activity is integral to all fundamental brain functions, including the processes of sensation, thought, emotion and memory. Because of this, dysfunction of AMPARs causes serious neurological disorders. In particular, one subclass of AMPARs that allow the entry of calcium ions into cells is implicated in the aetiology of several conditions, including multiple sclerosis, motor neuron disease, epilepsy, brain damage following stroke or during birth, and brain tumor growth. As AMPARs play a key role in normal cognition, they are also targets for drug treatments aimed at enhancing cognitive function, notably in neurodegenerative conditions such as Parkinson's and Alzheimer's disease. Understanding AMPARs is essential if we are to dissect their role in disease pathogenesis. Specifically, there is an urgent need to determine the principles that govern AMPAR function at a cellular and molecular level. Recently, our understanding of these processes advanced significantly, with the identification of proteins that directly associate with AMPARs and dictate their properties and behaviour. Two families of proteins have received particular attention - the transmembrane AMPAR regulatory proteins (TARPs) and the cornichons (CNIHs). Our research is aimed at understanding how these 'auxiliary subunits' control the function of AMPA receptors, with the goal of identifying potential avenues for therapeutic intervention. We will use a combination of proven electrophysiology, imaging and molecular approaches to address three specific goals: (1) to reveal how different auxiliary proteins affect the way in which endogenous molecules and exogenous drugs block or potentiate different classes of AMPARs; (2) to identify the specific auxiliary molecules important for the regulation of calcium-permeable AMPARs, and (3) to elucidate the role played by auxiliary proteins in AMPAR changes thought to underlie pathological conditions involving nerve cells and glia (inflammatory pain and white matter damage). Potential applications and benefits of this research stem from the fact that it will provide fundamental information about the regulation of an important class of glutamate receptors in nerve cells and glia. It will consolidate our understanding of normal brain function and highlight strategies for treatment of debilitating conditions. By establishing how different auxiliary proteins affect the pharmacology of specific AMPAR subtypes it has the potential to inform new efforts in drug discovery.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know